World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
77
Citations
28212
World Ranking
18288
National Ranking
70

Won Ki Kang publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Won Ki Kang sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 544 publications — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Won Ki Kang D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Won Ki Kang sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 77 D-Index — 10th percentile

10% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Won Ki Kang is affiliated with Samsung Medical Center in South Korea and has a research focus primarily within the field of Medicine. Their published work spans subfields including Oncology, Pulmonary and Respiratory Medicine, Surgery, Cancer Research, and Molecular Biology.

Their recent scientific contributions include studies in gastric cancer and immunotherapy with the following notable papers:

  • "A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial" (2020), published in Annals of Oncology
  • "Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer" (2021), published in Cancer Discovery
  • "Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab" (2021), published in Gastric Cancer
  • "Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer" (2020), published in Frontiers in Oncology
  • "Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer" (2020), published in Translational Cancer Research

Won Ki Kang often publishes in journals with a clinical oncology focus. Frequent publication venues include:

  • Journal of Clinical Oncology
  • Therapeutic Advances in Medical Oncology
  • Annals of Oncology
  • Gastric Cancer
  • Cancers

The scientist's collaborative network is notable, with frequent coauthors including:

  • Jeeyun Lee
  • Seung Tae Kim
  • Jung Yong Hong
  • Ho Yeong Lim
  • Joon Oh Park

Research topics covered extensively by Won Ki Kang encompass:

  • Gastric Cancer Management and Outcomes
  • Cancer Immunotherapy and Biomarkers
  • Colorectal Cancer Treatments and Studies
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Gastrointestinal Tumor Research and Treatment
  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics

Best Publications

  • Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Yoon Koo Kang;Narikazu Boku;Taroh Satoh;Min Hee Ryu

  • Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

    Razvan Cristescu;Jeeyun Lee;Michael Nebozhyn;Kyoung-Mee Kim

  • Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

    Seung Tae Kim;Razvan Cristescu;Adam J. Bass;Kyoung Mee Kim

  • Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

    Jung Hun Kang;Soon Il Lee;Do Hyoung Lim;Keon Woo Park

  • Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial

    Jeeyun Lee;Do Hoon Lim;Sung Kim;Se Hoon Park

  • Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study

    Jeeyun Lee;Se Hoon Park;Heung Moon Chang;Jun Suk Kim

  • Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses

    Se Hoon Park;Tae Sung Sohn;Jeeyun Lee;Do Hoon Lim

  • Clinical significance of four molecular subtypes of gastric cancer identified by The Cancer Genome Atlas project

    Bo Hwa Sohn;Jun Eul Hwang;Hee Jin Jang;Hee Jin Jang;Hyun Sung Lee

  • An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.

    Sung Kim;Do Hoon Lim;Jeeyun Lee;Won Ki Kang

  • Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.

    Filippo Pietrantonio;Rosalba Miceli;Alessandra Raimondi;Young Woo Kim

  • The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma

    Sarah Park;Jeeyun Lee;Young Hyeh Ko;Arum Han

  • Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype

    Sang Cheul Oh;Sang Cheul Oh;Bo Hwa Sohn;Jae Ho Cheong;Sang Bae Kim

  • Measuring Response in Solid Tumors: Comparison of RECIST and WHO Response Criteria

    Joon Oh Park;Soon I. I. Lee;Seo Young Song;Kihyun Kim

  • Safety and efficacy of nivolumab in combination with s-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (attraction-4)

    N. Boku;M.-H. Ryu;K. Kato;H.C. Chung

  • CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?

    W. S. Kim;S.-Y. Song;Y. C. Ahn;Y.-H. Ko

  • Phase II study of sunitinib as second-line treatment for advanced gastric cancer

    Yung Jue Bang;Yoon Koo Kang;Won K. Kang;Narikazu Boku

  • Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas

    Suling J. Lin;Johann A Gagnon-Bartsch;Iain Beehuat Tan;Sophie Earle

  • Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy.

    Jeeyun Lee;Yeon Hee Park;Won Seog Kim;Seung-Sook Lee

  • Malignant obstruction of gastric outlet and duodenum: palliation with flexible covered metallic stents.

    Kwang Bo Park;Young Soo Do;Won Ki Kang;Sung Wook Choo

  • A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

    Li Tzong Chen;Taroh Satoh;Min Hee Ryu;Yee Chao

Frequent Co-Authors

Jeeyun Lee
Jeeyun Lee Sungkyunkwan University
Joon Oh Park
Joon Oh Park Samsung Medical Center
Ho Yeong Lim
Ho Yeong Lim Samsung Medical Center
Keunchil Park
Keunchil Park The University of Texas MD Anderson Cancer Center
Se-Hoon Lee
Se-Hoon Lee Sungkyunkwan University
Yoon-Koo Kang
Yoon-Koo Kang Asan Medical Center
Jin Seok Ahn
Jin Seok Ahn Sungkyunkwan University
Ki-Hyun Kim
Ki-Hyun Kim Hanyang University
Woong-Yang Park
Woong-Yang Park Samsung Medical Center
Narikazu Boku
Narikazu Boku St. Marianna University School of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternatives to the traditional path of studying medicine in the USA can open diverse career opportunities in healthcare. Prospective students often seek faster or more affordable ways to enter or advance in the field. For those interested in nursing, a 6 month lpn program offers a quick route to becoming a Licensed Practical Nurse, providing hands-on experience and a foundation for further education.

If you already hold a nursing degree, the fastest psych np program can help you specialize in psychiatric-mental health, responding to a rising demand for mental health professionals. Meanwhile, those interested in healthcare leadership might consider an online healthcare administration degree, which covers organizational, financial, and strategic aspects of healthcare services.

For experienced professionals aiming for executive roles, the cheapest mha online programs provide a cost-effective way to earn a respected advanced degree. These flexible online options make it easier to balance studies with work or family commitments, helping you accelerate your career in the dynamic healthcare sector.

Best Scientists Citing Won Ki Kang

Trending Scientists

Recently Published Articles